Exercise in Metastatic Breast Cancer: EMBody

Eligibility Criteria

• 1. Age ≥ 18 years
• 2. Diagnosis of metastatic breast cancer
• 3. No progression of disease in the 12 months prior to screening per the treating investigator
• 1. If participant has changed treatments in the prior 12 months for reasons other than progressive disease, they remain eligible
• 2. Participants on no treatment or "no evidence of disease" but still with a diagnosis of metastatic breast cancer are eligible
• 4. ECOG performance status of 0-2
• 5. Ability to walk on a treadmill without assistive device.
• 6. Informed consent and authorization of the release of health information must be obtained according to institutional guidelines
• 7. Currently not meeting physical activity guidelines (defined as less than 150 minutes of moderate to vigorous exercise per week measured by the RPAQ questionnaire administered during screening)
• 8. Participants should have a cellular device compatible with iOS 15 or Android operating system 7.
• 1. Receiving cytotoxic chemotherapy at any point in the prior 12 months.
• 1. Participants receiving endocrine therapy are eligible.
• 2. Participants receiving targeted therapy or antibody therapy are eligible (examples including trastuzumab, pertuzumab, TDM-1, trastuzumab deruxtecan, sacituzumab govetecan, immunotherapy, CDK4/6 inhibitors, olaparib, alpelisib, etc.)
• 2. Any condition precluding supervised exercise participation. A letter from a physician supporting participation can supercede this eligibility criteria.
• * NYHA class III or IV congestive heart failure
• * Uncontrolled angina
• * Myocardial infarction in the prior 12 months
• * Orthopedic surgery in the previous 3 months or plans for orthopedic surgery during the study period
• * Chronic uncontrolled pulmonary conditions such as uncontrolled asthma (symptoms \> 2 days/week) or dyspnea requiring oxygen
• * Symptomatic peripheral vascular disease
• * Or any other comorbidity that would interfere with the ability to complete and comply with the protocol in the opinion of the investigator, including psychological illness
• * History of fragility fracture
• 3. Active, untreated brain metastases